Infusion site adverse events in breast cancer patients receiving highly emetic chemotherapy with prophylactic anti‑emetic treatment with aprepitant and fosaprepitant: A retrospective comparison

Hesketh PJ, Warr DG, Street JC and Carides AD: Differential time course of action of 5-HT3 and NK1 receptor antagonists when used with highly and moderately emetogenic chemotherapy (HEC and MEC). Support Care Cancer. 19:1297–1302. 2011. View Article : Google Scholar : PubMed/NCBI

Herrstedt J, Muss HB, Warr DG, Hesketh PJ, Eisenberg PD, Raftopoulos H, Grunberg SM, Gabriel M, Rodgers A, Hustad CM, et al: Efficacy and tolerability of aprepitant for the prevention of chemotherapy-induced nausea and emesis over multiple cycles of moderately emetogenic chemotherapy. Cancer. 104:1548–1555. 2005. View Article : Google Scholar : PubMed/NCBI

Herrington JD, Jaskiewicz AD and Song J: Randomized, placebo-controlled, pilot study evaluating aprepitant single dose plus palonosetron and dexamethasone for the prevention of acute and delayed chemotherapy-induced nausea and vomiting. Cancer. 112:2080–2087. 2008. View Article : Google Scholar : PubMed/NCBI

Rapoport BL, Jordan K, Boice JA, Taylor A, Brown C, Hardwick JS, Carides A, Webb T and Schmoll HJ: Aprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with a broad range of moderately emetogenic chemotherapies and tumor types: A randomized, double-blind study. Support Care Cancer. 18:423–431. 2010. View Article : Google Scholar : PubMed/NCBI

Basch E, Prestrud AA, Hesketh PJ, Kris MG, Feyer PC, Somerfield MR, Chesney M, Clark-Snow RA, Flaherty AM, Freundlich B, et al: Antiemetics: American society of clinical oncology clinical practice guideline update. J Clin Oncol. 29:4189–4198. 2011. View Article : Google Scholar : PubMed/NCBI

Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, et al: Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: Randomized, double-blind study protocol-EASE. J Clin Oncol. 29:1495–1501. 2011. View Article : Google Scholar : PubMed/NCBI

Leal AD, Kadakia KC, Looker S, Hilger C, Sorgatz K, Anderson K, Jacobson A, Grendahl D, Seisler D, Hobday T and Loprinzi CL: Fosaprepitant-induced phlebitis: A focus on patients receiving doxorubicin/cyclophosphamide therapy. Support Care Cancer. 22:1313–1317. 2014. View Article : Google Scholar : PubMed/NCBI

Sato Y, Kondo M, Inagaki A, Komatsu H, Okada C, Naruse K, Sahashi T, Kuroda J, Ogura H, Uegaki S, et al: Highly frequent and enhanced injection site reaction induced by peripheral venous injection of fosaprepitant in anthracycline-treated patients. J Cancer. 5:390–397. 2014. View Article : Google Scholar : PubMed/NCBI

Fujii T, Nishimura N, Urayama KY, Kanai H, Ishimaru H, Kawano J, Takahashi O, Yamauchi H and Yamauchi T: Differential impact of fosaprepitant on infusion site adverse events between cisplatin and anthracycline-based chemotherapy regimens. Anticancer Res. 35:379–383. 2015.PubMed/NCBI

Lundberg JD, Crawford BS, Phillips G, Berger MJ and Wesolowski R: Incidence of infusion-site reactions associated with peripheral intravenous administration of fosaprepitant. Support Care Cancer. 22:1461–1466. 2014. View Article : Google Scholar : PubMed/NCBI